Silver Book Fact

Improvements in QoL from TAVR in SAS patients

Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state) to 6.7 at one year, and 7.4 at four years post procedure.

Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8): 1039-46. https://www.pcronline.com/eurointervention/105th_issue/volume-12/number-8/169/four-year-experience-with-the-corevalve-transcatheter-heart-valve.html

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR improves quality of life in SAS patients
     
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • In 2010, ~67,500 SAVRs were performed in the U.S.